REFERENCES
-
1
Winblad B.
Piracetam: a review of pharmacological properties and clinical uses.
CNS Drug Rev.
2005;
11
(2)
169-182
-
2
Rossillon D, Vanwyck R, Bayet B, Calteux N, De Coninck A.
The action of piracetam in ischaemic flaps.
Br J Plast Surg.
1987;
40
(5)
459-466
-
3
Jordan L C, Hillis A E.
Disorders of speech and language: aphasia, apraxia and dysarthria.
Curr Opin Neurol.
2006;
19
(6)
580-585
-
4
Huber W.
The role of piracetam in the treatment of acute and chronic aphasia.
Pharmacopsychiatry.
1999;
32
(Suppl 1)
38-43
Review
-
5
Hamberg P, De Jong F A, Brandsma D, Verweij J, Sleijfer S.
Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature.
Acta Oncol.
2008;
47
(5)
974-978
-
6
Disa J J, Polvora V P, Pusic A L, Singh B, Cordeiro P G.
Dextran-related complications in head and neck microsurgery: do the benefits outweigh the risks? A prospective randomized analysis.
Plast Reconstr Surg.
2003;
112
(6)
1534-1539
Serhan TuncerM.D.
Department of Plastic Reconstructive and Aesthetic Surgery, Faculty of Medicine
14th Floor, Besevler, Ankara, Turkey
Email: serhantuncer74@yahoo.com
